Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 8—August 2015

Differentiation of Acute Q Fever from Other Infections in Patients Presenting to Hospitals, the Netherlands1

Stephan P. KeijmelComments to Author , Elmer Krijger, Corine E. Delsing, Tom Sprong, Marrigje H. Nabuurs-Franssen, and Chantal P. Bleeker-Rovers
Author affiliations: Radboud university medical center, Nijmegen, the Netherlands (S.P. Keijmel, E. Krijger, C.P. Bleeker-Rovers); Medical Spectrum Twente, Enschede, the Netherlands (C.E. Delsing); Canisius Wilhelmina Hospital, Nijmegen (T. Sprong, M.H. Nabuurs-Franssen)

Main Article

Table 7

Outcome, follow-up, and prophylaxis for patients with acute Q fever and control group with negative serologic results for Q fever, the Netherlands*

Characteristic Study group Control group p value
Hospitalized 57/82 (70) 49/52 (94) 0.001†
Need for ICU 2/57 (4) 9/49 (18) 0.002†
Need for respiratory support 1/57 (2) 8/49 (16) 0.001†
Mean ± SD duration of hospitalization, d 9 ± 7 17 ± 15 0.001‡
Mean ± SD duration of time in ICU, d 5 ± 1 14 ± 10 0.266‡
Follow up
Development of chronic Q fever 6/59 (10) NA NA
Development of long-lasting fatigue§ 6/56 (11) NA NA
Death 5/82 (6) 10/52 (19) 0.019†
Q fever–related death 1/82 (1)¶ NA NA
Indication for prophylaxis 16/82 (20) NA NA
Development of chronic Q fever
Prophylactic treatment 0/8 (0) NA NA
No prophylactic treatment 3/6 (50) NA 0.018#

*Values are no. positive/no. tested (%) unless otherwise indicated. ICU, intensive care unit; NA, not applicable.
†By χ2 test.
‡By Student t-test.
§Defined as persisting fatigue for >6 mo after acute Q fever in the absence of chronic Q fever.
¶This patient died of consequences of an infected vascular prosthesis caused by chronic Q fever.
#By unilateral Barnard exact test.

Main Article

1Preliminary results from this study were presented as a poster (P1851) at the 22th annual European Congress of Clinical Microbiology and Infectious Diseases, March 31–April 3, 2012, London, UK.

Page created: July 14, 2015
Page updated: July 14, 2015
Page reviewed: July 14, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.